Leading pharma company, Lupin Limited (Lupin) has said that there has been successful completion of a PAI inspection (Prior Approval Inspection) carried out by the US FDA at its Goa manufacturing facility without any observations. The inspection which started on Monday, July 17th concluded on July 21st.
Lupin is the 4th and the 6th largest generics pharmaceutical company by market capitalization and revenues globally. The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); the 2nd largest Indian pharmaceutical company by global revenues; the 6th largest generic pharmaceutical player in Japan and the 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT March 2017).
Meanwhile, shares of the company were trading at Rs 1152 apiece, up 0.80 per cent from the previous close at 09:30 hours on BSE.